Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.
“Boehringer Ingelheim Pharmaceuticals, Inc. is committed to ensuring that its medicines are accessible and affordable to all patients, including through the 340B program,” BI Senior Vice President, Market Access Chris Marsh said in a statement. “Our carefully tailored contract pharmacy policy is fully compliant with the 340B statute and is intended to help ensure that 340B discounts benefit the patients of covered entities.”
Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
